13D Filing: Avego Healthcare Capital, LLC and Acer Therapeutics Inc. (ACER)

            The
percentages of beneficial ownership reported in this Schedule 13D are based on
6,453,260 Common Shares of beneficial interest of the Issuer outstanding as of
September 19, 2017, following the completion of the Issuers Merger, such number
of shares being based on information made publicly available by the Issuer.

            To
the Reporting Persons knowledge, as of September 28, 2017, none of the other
individuals named in Item 2 of this Schedule 13D beneficially own any Common
Shares.

            (c)
Transactions effected in the past sixty days.

            There
have been no reportable transactions with respect to the Common Shares within
the last 60 days by the Reporting Persons, except as described in this Schedule
13D.

            (d)        No
other person is known to have the right to receive, or the power to direct the
receipt of dividends from, or the proceeds from the sale of, the securities
covered by this Schedule 13D.

            (e)        Not
applicable.

Item 6. Contracts, Arrangements, Understandings or
Relationships with Respect to Securities of the Issuer

            Except
as set forth herein, there are no contracts, arrangements, understandings or
relationships among the persons named in Item 2 or between such persons and any
other person with respect to the shares reported.

Item 7. Material to Be Filed as Exhibits

            Exhibit
1: Joint Filing Agreement, dated September 28, 2017 by and among the Reporting
Persons.

10